Table 2

Susceptibility of XMRV and HIV-1 to integrase inhibitors.

EC₅₀ (nM)^a

Inhibitor

HIV-1_NL4-3

XMRV_VP62+LtatSN^b

XMRV_22Rv1+LtatSN^b

raltegravir

3.7 ± 2.1

2.1 ± 1.1 (1)

2.2 ± 1.1 (1)

elvitegravir

1.9 ± 0.7

150 ± 115 (79)

87 ± 29 (46)

^a EC₅₀ values were measured in MAGIC-5A cells as described in Methods and are the means ± standard deviation from two or more independent experiments. Numbers in parentheses indicate the fold change in EC₅₀ relative to HIV-1_NL4-3. Values shown in bold are significantly different from the corresponding values for HIV-1_NL4-3 (p < 0.05, ANOVA with Tukey's multiple comparison test).

^b XMRV-pseudotyped LtatSN virus. See text for details.

Smith et al. Retrovirology 2010 7:70   doi:10.1186/1742-4690-7-70